Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update

References

• Potena L, Holweg CT, Vana ML, et al. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol. 2007;45:1804–1810.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–360.
   PubMed Web of Science ®Google Scholar
• Cytomegalovirus NS. Textbook of human virology. St. Louis, MO: Mosby-Year Book Inc; 1991. p. 889–924.
   Google Scholar
• Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002;10:332–339.
   PubMed Web of Science ®Google Scholar
• Kudchodkar SB, Yu Y, Maguire TG, et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol. 2004;78:11030–11039.
   PubMed Web of Science ®Google Scholar
• Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005;79:381–386.
   PubMed Web of Science ®Google Scholar
• Thomas LD, Milstone AP, Miller GG, et al. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant. 2009;23:476–483.
   PubMed Web of Science ®Google Scholar
• Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007;20:425–431.
   PubMed Web of Science ®Google Scholar
• Solidoro P, Balestro E, Boffini M. Viral infections in lung transplant recipients: devils or trolls? Minerva Med. 2014;105(Suppl 2–3):15–21.
   Google Scholar
• Kumar D, Humar A. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am. 2010;24:395–412.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Limaye AP, Potena L, et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43:S1–S17.
   PubMed Web of Science ®Google Scholar
• Prisbe EJ, Martin JC, McGee DP, et al. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. J Med Chem. 1986;29:671–675.
   PubMed Web of Science ®Google Scholar
• Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866–872.
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689–712.
   PubMed Web of Science ®Google Scholar
• Ds O, Webster AC, Strippoli GF, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD005133.
   Google Scholar
• Em H, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD003774.
   Google Scholar
• Devyatko E, Zuckermann A, Ruzicka M, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant. 2004;23:1277–1282.
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. Oral Ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620.
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106–2113.
   PubMed Web of Science ®Google Scholar
• Gagermeier JP, Rusinak JD, Lurain NS, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014;16:941–950.
   PubMed Web of Science ®Google Scholar
• Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA. 2000;97:8039–8044.
   PubMed Web of Science ®Google Scholar
• McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153–1183.
   PubMed Web of Science ®Google Scholar
• Le Page AK, Jager MM, Kotton CN, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95:1455–1460.
   PubMed Web of Science ®Google Scholar
• Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228–1237.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761–769.
   PubMed Web of Science ®Google Scholar
• Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant. 2008;8:2111–2118.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Freifeld AG, Lyden ER, et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One. 2009;4:e5512.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52:313–321.
   PubMed Web of Science ®Google Scholar
• Avery RK. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more? Clin Infect Dis. 2011;52:322–324.
   PubMed Web of Science ®Google Scholar
• Prentice HG. Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother. 1983;12 (Suppl B):153–159.
   PubMed Web of Science ®Google Scholar
• Meyers JD, Wade JC, McGuffin RW, et al. The use of acyclovir for cytomegalovirus infections in the immunocompromised host. J Antimicrob Chemother. 1983;12(Suppl B):181–193.
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462–1470.
   PubMed Web of Science ®Google Scholar
• Flechner SM, Avery RK, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation. 1998;66:1682–1688.
   PubMed Web of Science ®Google Scholar
• Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 1994;150:146–152.
   PubMed Web of Science ®Google Scholar
• Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90:672–676.
   PubMed Web of Science ®Google Scholar
• Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8:69–77.
   PubMed Web of Science ®Google Scholar
• Reischig T, Kacer M, Jindra P, et al. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol: CJASN. 2015;10:294–304.
   PubMed Web of Science ®Google Scholar
• Kielberger L, Bouda M, Jindra P, et al. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res. 2012;35:407–416.
   PubMed Web of Science ®Google Scholar
• Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23:1588–1597.
   PubMed Web of Science ®Google Scholar
• Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58:128–135.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–649.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–27.
   PubMed Web of Science ®Google Scholar
• Tischler V, Schuurmans MM, Boehler A, et al. Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. J Heart Lung Transplant. 2012;31:1037–1040.
   PubMed Web of Science ®Google Scholar
• Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162–170.
   PubMed Web of Science ®Google Scholar
• Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The cytomegalovirus retreatment trial. the studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Arch Ophthalmol. 1996;114:23–33.
   PubMedGoogle Scholar
• Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation. 2013;95:1015–1020.
   PubMed Web of Science ®Google Scholar
• Andrei G, Topalis D, De Schutter T, et al. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia. Antiviral Res. 2015;114:21–46.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis. 2014;27:554–559.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12:3021–3030.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227–1236.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–1789.
   PubMed Web of Science ®Google Scholar
• Roy S, Arav-Boger R. New cell-signaling pathways for controlling cytomegalovirus replication. Am J Transplant. 2014;14:1249–1258.
   PubMed Web of Science ®Google Scholar
• Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis. 1999;1(Suppl 1):8–12.
   PubMedGoogle Scholar
• Grossi P, Mohacsi P, Szabolcs Z, et al. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100:s1–s3.
   Google Scholar
• Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12–28.
   PubMed Web of Science ®Google Scholar
• Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100:S11–S8.
   PubMed Web of Science ®Google Scholar
• Sarmiento E, Lanio N, Gallego A, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol. 2009;9:649–652.
   PubMed Web of Science ®Google Scholar
• Yamani MH, Avery R, Mawhorter SD, et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant. 2005;24:1766–1769.
   PubMed Web of Science ®Google Scholar
• Bonaros NE, Kocher A, Dunkler D, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation. 2004;77:890–897.
   PubMed Web of Science ®Google Scholar
• Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant. 2003;22:754–763.
   PubMed Web of Science ®Google Scholar
• Metselaar HJ, Balk AH, Mochtar B, et al. Cytomegalovirus seronegative heart transplant recipients. Prophylactic Use of Anti-Cmv Immunoglobulin. Chest. 1990;97:396–399.
   PubMed Web of Science ®Google Scholar
• Balk AH, Weimar W, Rothbarth PH, et al. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience. Infection 1993;21:195–200.
   PubMed Web of Science ®Google Scholar
• Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398–405.
   PubMed Web of Science ®Google Scholar
• Solidoro P, Delsedime L, Costa C, et al. Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation. New Microbiol. 2011;34:33–36.
   PubMed Web of Science ®Google Scholar
• Solidoro P, Libertucci D, Delsedime L, et al. Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections. Transplant Proc. 2008;40:2013–2014.
   PubMed Web of Science ®Google Scholar
• Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415–1420.
   PubMed Web of Science ®Google Scholar
• Weill D, Lock BJ, Wewers DL, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant. 2003;3:492–496.
   PubMed Web of Science ®Google Scholar
• Carbone J, Sarmiento E, Palomo J, et al. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Transplant Proc. 2007;39:2385–2388.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009;88:1–6.
   PubMed Web of Science ®Google Scholar
• Shulz U, Solidoro P, Muller V, et al. CMV immunoglobulins for the treatment of cmv infections in thoracic transplant recipients. Transplantation. 2016;100:S5–S10.
   Google Scholar
• Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 2010;10:1881–1888.
   PubMed Web of Science ®Google Scholar
• Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007;84:1436–1442.
   PubMed Web of Science ®Google Scholar
• Potena L, D’Agostino C, Abate D, et al. Interaction of CMV prophylaxis and pre-emptive strategies with immunosuppressive therapy: potential antiviral effect of everolimus. J Heart Lung Transplant. 2010;29:S155–S6.
   Google Scholar
• Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13:1203–1216.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150–162.
   PubMed Web of Science ®Google Scholar
• Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075–1085.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Aguado JM, Potena L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23:97–125.
   PubMed Web of Science ®Google Scholar
• Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008;40:1407–1410.
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol. 2011;85:3930–3939.
   PubMed Web of Science ®Google Scholar
• Li Q, Rao RR, Araki K, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity. 2011;34:541–553.
   PubMed Web of Science ®Google Scholar
• Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev. 2010;235:234–243.
   PubMed Web of Science ®Google Scholar
• Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant. 2012;12:1458–1468.
   PubMed Web of Science ®Google Scholar
• De Pablo A, Santos F, Sole A, et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev (Orlando). 2013;27:9–16.
   PubMedGoogle Scholar
• Ritta M, Costa C, Solidoro P, et al. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res. 2015;113:19–26.
   PubMed Web of Science ®Google Scholar
• Glanville AR, Aboyoun C, Klepetko W, et al. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. J Heart Lung Transplant. 2015;34:16–25.
   PubMed Web of Science ®Google Scholar
• Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6:986–992.
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005;5:218–227.
   PubMed Web of Science ®Google Scholar
• Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol. 2006;16:281–287.
   PubMed Web of Science ®Google Scholar
• Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 2001;11:83–86.
   PubMed Web of Science ®Google Scholar
• Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol. 2006;16:289–295.
   PubMed Web of Science ®Google Scholar
• Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6:2134–2143.
   PubMed Web of Science ®Google Scholar
• Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28:461–467.
   PubMed Web of Science ®Google Scholar
• Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402–2410.
   PubMed Web of Science ®Google Scholar
• Puius YA, Snydman DR. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Curr Opin Infect Dis. 2007;20:419–424.
   PubMed Web of Science ®Google Scholar
• Perciaccante B, Bianchi G, Potena L, et al. Everolimus and valganciclovir prophylaxis: how to chase CMV but not the patient: insights from PROTECT randomized study. J Heart Lung Transpl. 2015;34:S305.
   Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779–795.
   PubMed Web of Science ®Google Scholar
• Gerna G, Baldanti F, Torsellini M, et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir Ther. 2007;12:63–72.
   PubMed Web of Science ®Google Scholar
• Sanghavi SK, Abu-Elmagd K, Keightley MC, et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol. 2008;42:335–342.
   PubMed Web of Science ®Google Scholar
• Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013;56:13–18.
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Rognoni V, et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant. 2009;9:1142–1150.
   PubMed Web of Science ®Google Scholar
• Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355:2032–2036.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 2009;32:245–253.
   PubMed Web of Science ®Google Scholar
• Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9:258–268.
   PubMed Web of Science ®Google Scholar
• Hayden RT, Preiksaitis J, Tong Y, et al. Commutability of the first world health organization international standard for human cytomegalovirus. J Clin Microbiol. 2015;53:3325–3333.
   PubMed Web of Science ®Google Scholar
• Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol. 2007;45:324–328.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Bruno F, et al. Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients. New Microbiol. 2013;36:267–277.
   PubMed Web of Science ®Google Scholar
• Costa C, Curtoni A, Sidoti F, et al. Detection of human cytomegalovirus in transbronchial biopsies from lung transplant recipients. Arch Virol. 2013;158:1461–1465.
   PubMed Web of Science ®Google Scholar
• Ke S, Lyu DM, Grazia TJ, et al. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant. 2013;13:376–382.
   PubMed Web of Science ®Google Scholar
• Costa C, Saldan A, Sinesi F, et al. The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. Int J Immunopathol Pharmacol. 2012;25:1003–1009.
   PubMed Web of Science ®Google Scholar
• Lazzarotto T, Varani S, Spezzacatena P, et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis. 1998;178:1145–1149.
   PubMed Web of Science ®Google Scholar
• Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114:1608–1615.
   PubMed Web of Science ®Google Scholar
• Egli A, Silva M Jr., O’Shea D, et al. An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One. 2012;7:e43937.
   PubMed Web of Science ®Google Scholar
• Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant. 2008;8:1749–1754.
   PubMed Web of Science ®Google Scholar
• Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56:817–824.
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Kumar D, Wilson LE, et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93:195–200.
   PubMed Web of Science ®Google Scholar
• Westall GP, Cristiano Y, Peleg AY, et al. Interim analysis: a study of quantiFERON-CMV-Directed CMV prophylaxis versus standard-of-care to reduce late cmv reactivation in patients undergoing lung transplantation. J Heart Lung Transplant. 2016;35:S105.
   Google Scholar
• Solidoro P, Costa C, Libertucci D, et al. Tailored cytomegalovirus management in lung transplant recipient: a single-center experience. Transplant Proc. 2013;45:2736–2740.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine. 2013;31(Suppl 2):B197–B203.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256–1263.
   PubMed Web of Science ®Google Scholar